Share

May 2017; 4 (3) EditorialOpen Access

Foveal thinning in neuromyelitis optica

A sign of retinal astrocytopathy?

Takashi Yamamura, Ichiro Nakashima
First published April 11, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000347
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
661

Share

Article Information

vol. 4 no. 3 e347
DOI: 
https://doi.org/10.1212/NXI.0000000000000347
PubMed: 
28439528
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published April 11, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Takashi Yamamura, MD, PhD and
    2. Ichiro Nakashima, MD, PhD
  1. Takashi Yamamura, MD, PhD and
    2. Scientific Advisory Boards:

    1. (1)Biogen Japan (2) Chugai Pharmaceutical Co., Ltd (3) Takeda Pharamaceutical Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Novartis Pharma (2) Nihon Pharmaceutical Co., Ltd., (3) Santen Pharmaceutical Co., Ltd., (4) Abbott Japan Co., Ltd./Eisai Co., Ltd., (5) Biogen Japan, (6) Dainippon Sumitomo Pharma Co., Ltd., (7) Bayer Holding Ltd., (8) Astellas Pharma Inc. (9) Takeda Pharamaceutical Co.

    Editorial Boards:

    1. Clinical and Experimental Neuroimmunology, Editor, since 2010

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Ono Pharmaceutical Co., Ltd., (2) Chugai Pharmaceutical Co., Ltd., (3) Teva Pharmaceutical K.K., (4) Mitsubishi Tanabe Pharma Corporation, (5) Asahi Kasei Kuraray Medical CO., Ltd.

    Research Support, Government Entities:

    1. (1) Ministry of Health, Labour and Welfare of Japan, the Health and Labour Sciences Research Grants on Intractable Diseases (Neuroimmunological Diseases), investigator, since 2010.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ichiro Nakashima, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Received funding for a trip and speaks from Mitsubishi Tanabe Pharma (2012-2016) and Novartis Pharma (2012-2015).

    Editorial Boards:

    1. Served as an editorial board member of Multiple Sclerosis International(2010-present).

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received grant support from LSI Medience Corporation (2012-2016).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.
  1. Correspondence to Dr. Yamamura: yamamura{at}ncnp.go.jp
View Full Text

Article usage

Article usage: April 2017 to August 2018

AbstractFullPdfSource
Apr 2017465pmc
May 201793435pmc
Jun 201751718pmc
Jul 2017298pmc
Aug 201751820pmc
Sep 201721212pmc
Oct 201752321pmc
Nov 201731212pmc
Apr 2018187pmc
Jun 2018189pmc
Aug 201811010pmc

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me